Liraglutide US approval delay
Partner's US approval for liraglutide is delayed; additional data submitted in January 2026. If approval does not come through, revenue may be partially offset by European demand.
medium · analyst_questionGland Pharma Limited — Q3 FY26
Gland Pharma delivered a strong Q3 FY26 with consolidated revenue of ₹1,695 crore, up 22% YoY, driven by broad-based growth across markets and a turnaround at Synexi.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Capacity constraints limiting growth
Existing lines are running at 80-90% utilization, with some at full capacity. New capacity additions are needed within 2 years to sustain growth.
medium · management_commentarySynexi quarterly volatility
Despite turnaround, Synexi's revenue may fluctuate quarter-to-quarter due to product mix and customer ordering patterns.
low · management_commentaryPricing pressure in US generics
US pricing declined 5-6% YoY, offset by cost efficiencies. Sustained pricing erosion could pressure margins if cost savings are not maintained.
medium · data_observation